Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD

European Respiratory Journal

Volumn 47, Issue 5, 2016, Pages 1365-1373

  Rabinovich, Roberto A ^a   Miller, Bruce E ^b   Wrobel, Karolina ^c   Ranjit, Kareshma ^a   Williams, Michelle C ^d   Drost, Ellen ^a   Edwards, Lisa D ^e   Lomas, David A ^f   Rennard, Stephen I ^g,h   Agustí, Alvar ⁱ   Tal Singer, Ruth ^b   Vestbo, Jørgen ^j   Wouters, Emiel F M ^k   John, Michelle ^l   Van Beek, Edwin J R ^m   Murchison, John T ⁿ   Bolton, Charlotte E ^l   Macnee, William ^a   Huang, Jeffrey T J ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e PAREXEL INTERNATIONAL   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^k MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^l UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^m CRIC (Clinical Research Imaging Centre)   (United Kingdom)

ⁿ ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DESMOSINE; ELASTIN; BIOLOGICAL MARKER; BRONCHODILATING AGENT;

ADULT; AGE; AGED; AIRWAY OBSTRUCTION; AMINO ACID BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY CALCIUM SCORE; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHYSICAL CAPACITY; PREDICTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PULSE WAVE; BLOOD; BODY COMPOSITION; CALCINOSIS; CASE CONTROL STUDY; COMPLICATION; CORONARY BLOOD VESSEL; DISEASE EXACERBATION; INFLAMMATION; LUNG EMPHYSEMA; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; SMOKING;

ADULT; AGED; BIOMARKERS; BODY COMPOSITION; BRONCHODILATOR AGENTS; CALCINOSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CORONARY VESSELS; DESMOSINE; DISEASE PROGRESSION; ELASTIN; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; PULSE WAVE ANALYSIS; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SMOKING; VASCULAR STIFFNESS;

EID: 84969785019     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01824-2015     Document Type: Article

References (41)

1. Rodriguez-Roisin R, Anzueto A, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.org/uploads/users/files/GOLDReport-April112011.pdf Date last accessed: March 2016. Date last updated: 2010.
2. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann Intern Med 2005; 142: 233-239.
3. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075.
4. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-415.
5. MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. Eur Respir J 2014; 44: 1332-1352.
6. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 513-520.
7. Shapiro SD. The pathogenesis of emphysema: The elastase:antielastase hypothesis 30 years later. Proc Assoc Am Physicians 1995; 107: 346-352.
8. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity improves cardiovascular event prediction: An individual participant meta-analysis of prospective observational data from 17, 635 subjects. J Am Coll Cardiol 2014; 63: 636-646.
9. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 1259-1265.
10. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: A mechanism for increased cardiovascular risk. Thorax 2008; 63: 306-311.
11. Gaballa MA, Jacob CT, Raya TE, et al. Large artery remodeling during aging: biaxial passive and active stiffness. Hypertension 1998; 32: 437-443.
12. Fornieri C, Quaglino D Jr, Mori G. Role of the extracellular matrix in age-related modifications of the rat aorta. Ultrastructural, morphometric, and enzymatic evaluations. Arterioscler Thromb 1992; 12: 1008-1016.
13. Robert L, Robert AM, Jacotot B. Elastin-elastase-atherosclerosis revisited. Atherosclerosis 1998; 140: 281-295.
14. Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012; 67: 606-612.
15. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 1208-1214.
16. Luisetti M, Ma S, Iadarola P, et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008; 32: 1146-1157.
17. Albarbarawi O, Barton A, Miller D, et al. Characterization and validation of an isotope-dilution LC-MS/MS method for quantification of total desmosine and isodesmosine in plasma and serum. Bioanalysis 2013; 5: 1991-2001.
18. Huang JT, Chaudhuri R, Albarbarawi O, et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax 2012; 67: 502-508.
19. Boutin M, Berthelette C, Gervais FG, et al. High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosine. Anal Chem 2009; 81: 1881-1887.
20. Lindberg CA, Engström G, de Verdier MG, et al. Total desmosines in plasma and urine correlate with lung function. Eur Respir J 2012; 39: 839-845.
21. Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31: 869-873.
22. John M, McKeever T, Al Haddad M, et al. Assessments of cardiovascular risk in patients with COPD. Chron Respir Dis 2016 [in press; DOI:10.117711479972316636995].
23. Dickens JA, Miller BE, Edwards LD, et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011; 12: 146.
24. Sin DD, Miller BE, Duvoix A, et al. Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183: 1187-1192.
25. Gietema HA, Müller NL, Fauerbach PV, et al. Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol 2011; 18: 661-671.
26. Coxson HO, Dirksen A, Edwards LD, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: A prospective analysis from the ECLIPSE study. Lancet Respir Med 2013; 1: 129-136.
27. Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 2014; 69: 718-723.
28. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827-832.
29. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605.
30. Starcher BC. Elastin and the lung. Thorax 1986; 41: 577-585.
31. Karnik SK, Brooke BS, Bayes-Genis A, et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development 2003; 130: 411-423.
32. Ma S, Turino GM, Lin YY. Quantitation of desmosine and isodesmosine in urine, plasma, and sputum by LC-MS/MS as biomarkers for elastin degradation. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 1893-1898.
33. Maurice P, Blaise S, Gayral S, et al. Elastin fragmentation and atherosclerosis progression: The elastokine concept. Trends Cardiovasc Med 2013; 23: 211-221.
34. Campa JS, Greenhalgh RM, Powell JT. Elastin degradation in abdominal aortic aneurysms. Atherosclerosis 1987; 65: 13-21.
35. Arribas SM, Hinek A, Gonzalez MC. Elastic fibres and vascular structure in hypertension. Pharmacol Ther 2006; 111: 771-791.
36. Smith ER, Tomlinson LA, Ford ML, et al. Elastin degradation is associated with progressive aortic stiffening and all-cause mortality in predialysis chronic kidney disease. Hypertension 2012; 59: 973-978.
37. Bizbiz L, Alpérovitch A, Robert L. Aging of the vascular wall: serum concentration of elastin peptides and elastase inhibitors in relation to cardiovascular risk factors. The EVA study. Atherosclerosis 1997; 131: 73-78.
38. Abboud RT, Vimalanathan S. Pathogenesis of COPD. Part I. The role of protease-antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 2008; 12: 361-367.
39. Man SF, Xing L, Connett JE, et al. Circulating fibronectin to C-reactive protein ratio and mortality: A biomarker in COPD?. Eur Respir J 2008; 32: 1451-1457.
40. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One 2012; 7: e37483.
41. Starcher B, Peterson B. The kinetics of elastolysis: elastin catabolism during experimentally induced fibrosis. Exp Lung Res 1999; 25: 407-424.